| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_ITCH_0024100 | Exon-Exon | chr20:33057853-33069011 | chr20:34470048-34481206 | 669 nt | 0.3871 |
| hsa_ITCH_0024200 | Exon-Exon | chr20:33057853-33077731 | chr20:34470048-34489926 | 895 nt | 0.3922 |
| hsa_ITCH_0024300 | Exon-Exon | chr20:33057853-33080402 | chr20:34470048-34492597 | 992 nt | 0.3931 |
| hsa_ITCH_0026600 | Exon-Exon | chr20:33059249-33067594 | chr20:34471444-34479789 | 367 nt | 0.3951 |
| hsa_ITCH_0026200 | Exon-Exon | chr20:33059249-33069011 | chr20:34471444-34481206 | 596 nt | 0.3775 |
| hsa_ITCH_0026300 | Exon-Exon | chr20:33059249-33080402 | chr20:34471444-34492597 | 919 nt | 0.3874 |
| hsa_ITCH_0026400 | Exon-Exon | chr20:33059249-33095713 | chr20:34471444-34507908 | 1206 nt | 0.3939 |
| hsa_ITCH_0027000 | Exon-Exon | chr20:33065577-33067594 | chr20:34477772-34479789 | 249 nt | 0.4016 |
| hsa_ITCH_0027100 | Exon-Exon | chr20:33065577-33068537 | chr20:34477772-34480732 | 383 nt | 0.3890 |
| hsa_ITCH_0027200 | Exon-Exon | chr20:33065577-33069011 | chr20:34477772-34481206 | 524 nt | 0.3740 |
A review consolidating research in humans and model organisms indicates that the circITCH functions as a tumor suppressor in glioma by sponging miR-214 to allow expression of ubiquitin-protein ligase E3, thereby suppressing proliferation and preventing apoptosis, while also targeting the Wnt/β-catenin pathway [Mehta et al. DOI:10.1016/j.pneurobio.2020.101746]. In oesophageal squamous cell carcinoma, the circITCH is downregulated and increases ITCH expression to inhibit the Wnt/β-catenin pathway [Lee et al. DOI:10.1016/j.biopha.2018.12.052]. circITCH hsa_circ_0001141 (circITCH) was found to be lower in the hearts of cancer patients suffering from doxorubicin-induced cardiomyopathy compared to those with dilated cardiomyopathy, hypertrophic cardiomyopathy, and healthy donors, and its expression ameliorates doxorubicin-induced cardiomyocyte injury [Tian et al. DOI:10.3390/molecules26041155].